Biographies

Dr. Christopher A. Kroeger, M.D. serves as Chief Executive Officer- Elect of the company. He will begin to serve as the Company’s Chief Executive Officer on September 1, 2017, at which time he will join the Company’s Board of Directors. Dr. Kroeger joins OvaScience from Cardioxyl Pharmaceuticals, Inc., where he served as chief executive officer and President from 2008 to December 2015. At Cardioxyl, Dr. Kroeger oversaw the preclinical and clinical development of a pipeline for acute and chronic heart failure, including CXL-1427, a potential treatment for acute decompensated heart failure. He also successfully negotiated Cardioxyl’s sale to Bristol Myers Squibb for $2.1 billion in total consideration. Prior to his position at Cardioxyl, he led biotechnology and medical device investing efforts at The Aurora Funds, a venture capital firm focused on early-stage healthcare and information technology companies, where he has held various positions since 2003. Dr. Kroeger has been a partner at The Aurora Funds from 2007 to the present. Earlier in his career, he held positions at Genzyme and Decision Resources. Dr. Kroeger earned his B.A. from Harvard University, his M.D. from Stanford University School of Medicine and did his Residency in General Surgery at the Brigham and Women’s Hospital, an affiliate of Harvard Medical School. He also holds his M.B.A. from Harvard Business School. Dr. Kroeger currently serves on the board of directors of CardioFocus, Inc., where he has served on the board since April 2006, and Cantex Pharmaceuticals, Inc., where he has served on the board since August 2006. He previously served as a director on the board of directors of three other Aurora Funds portfolio companies, including Cardioxyl, Neotropix and Hyperbranch, and he has worked with over a dozen biotechnology and medical device companies during his career.

Mr. Jonathan Gillis serves as principal Financial Officer, principal Accounting Officer, Vice President of the company. Mr. Gillis has served at OvaScience in various roles since June 2013, including Assistant Controller from June 2013 to January 2014, Controller from January 2014 to August 2015, and Senior Director of Global Finance & Operations from August 2015 to June 2017. Prior to joining the Company, Mr. Gillis was Senior Manager of External Reporting and Compliance at GFI Software, Inc. from January 2013 to June 2013 and Assistant Controller at Aspen Aerogels, Inc. from May 2012 to January 2013. Prior to that, Mr. Gillis worked at Birch Hill Partners, LLC and PricewaterhouseCoopers, LLP.

Ms. Karen Long has been appointed as Executive Vice President - Clinical and Regulatory Affairs and Quality Assurance of the Company. Karen Long joins OvaScience from Danaher, Leica Biosystems, where she was Vice President, Regulatory Affairs and Quality Assurance and oversaw the development of the company's quality management systems, regulatory, clinical research and compliance programs. Karen has more than 20 years of industry experience, including various senior positions in regulatory affairs at Abbott, Roche Molecular Systems, Inc., Calypte Biomedical Corporation and Baxter Healthcare Therapeutics. She holds a B.S. in Biochemistry and Medical Technology from the University of Illinois.

Dr. James Luterman, Ph.D., has been appointed as Executive Vice President - Research and Development of the Company. James Luterman, Ph.D. has been with OvaScience since January 2014 and brings over 20 years of industry experience to the Company. Most recently he served as Senior Vice President, Research and Development at OvaScience. Prior to OvaScience, Dr. Luterman held various positions at Shire Human Genetic Therapies. He also worked at Biogen and Decision Resources Group. He holds a B.A. in Biology and Psychology from Bucknell University and a Ph.D. in Behavioral and Neural Sciences from Rutgers University. Dr. Luterman was a postdoctoral fellow at Mount Sinai School of Medicine.

Theresa McNeely is Executive Vice President, Chief Communications Officer of the Company; since December 2014 and prior to this promotion, Ms. McNeely was our Executive Vice President, Strategic Corporate Communications from August 2012 to December 2014. Ms. McNeely has over 20 years of integrated corporate communications experience spanning investor relations, public relations, marketing communications, and patient advocacy in life sciences companies, including pharmaceutical and biotech, molecular diagnostics, tools and service providers. Prior to joining us, from August 2008 to July 2011, Ms. McNeely was Vice President of Corporate Communications at Clinical Data, Inc., a drug development company that was acquired by Forest Laboratories. Ms. McNeely has also held management positions at Millennium Pharmaceuticals, EXACT Sciences and Pyrosequencing. Earlier in her career Ms. McNeeley worked for Allen & Co., a boutique investment bank. She is a member of the advisory board of Cramer, a creative marketing studio. Ms. McNeely received her B.S. in Business Administration from Providence College, and an M.S. in Business Communications and Healthcare Communications from Simmons College.

Dr. James Lillie is appointed as Chief Scientific Officer of the company. He joined OvaScience from Sanofi Genzyme where he was Vice President, In Vitro Biology from 2007 through January 15, 2018. In this role, Dr. Lillie was responsible for developing a scientific strategy for creating a sustainable, high value portfolio in rare diseases. He established a strong pipeline of small molecule drugs and supported the U.S. Food and Drug Administration’s approval of Eliglustat and acceptance of two investigational new drug applications. Previously, he was Senior Director, In Vitro Biology at Sanofi Genzyme from 2004-2007 and, before that, he held roles of increasing responsibility at Millennium Pharmaceuticals, Inc. Earlier, he worked as Senior Director, Biology at Scriptgen Pharmaceuticals, and as co-founder at AMIRA, which was later sold to Repligen Corporation. Dr. Lillie holds a Ph.D. in Biochemistry and Molecular Biology from Harvard University and B.A. in German Literature from Wesleyan University.

Dr. Ravi Mehrotra, Ph.D., is Chief Corporate Development Officer of OvaScience, Inc. Dr. Mehrotra joins from Credit Suisse LLC where he served as Global Head of Biotechnology Equity Research since 2010 based in New York, leading the equity research team that covered more than 40 global biotechnology and life sciences companies. Dr. Mehrotra originally joined Credit Suisse in 2004 in London, U.K., and served as Head of European Biotechnology and EMEA Equity Research, being ranked the number one analyst in both European Institutional Investor and Extel surveys. Prior to that, he held positions of increasing responsibility at SG Cowen in London, including Head of European Biotechnology. Earlier in his career, he worked for Deutsche Bank (Natwest Markets/BT Alex Brown) in London. Dr. Mehrotra holds a Bachelor of Science in Biochemistry and a Ph.D. in Biochemistry and Molecular Biology from Manchester University.

Mr. Richard H. Aldrich serves as Lead Independent Director of OvaScience, Inc. Mr. Richard Aldrich co-founded our company in April 2011. He has served as a member of our board of directors since July 2011 and as the chairman of our board of directors since March 2012. Mr. Aldrich is a co-founder and partner of Longwood Fund, LP, a venture capital investment fund. He has co-founded and helped to build several successful biotech companies including Sirtris Pharmaceuticals, Inc. (acquired by GlaxoSmithKline in 2008); Concert Pharmaceuticals, Inc., where he serves as chairman of the board; Alnara Pharmaceuticals, Inc. (acquired by Eli Lilly in 2010); Verastem, Inc.,; and Flex Pharma, Inc., a biotechnology company developing treatments for symptoms associated with neuromuscular conditions. Mr. Aldrich also serves on the board of directors of PTC Therapeutics, Inc., Mitobridge, Inc. and Colorescience, Inc. Prior to co-founding Longwood, he was General Partner of RA Capital, a biotechnology investment fund he co-founded in 2001. Mr. Aldrich was also a founding employee of Vertex Pharmaceuticals, Inc., where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen, Inc. Mr. Aldrich serves on the Board of the Massachusetts Eye & Ear Infirmary and the Greater Boston YMCA. Mr. Aldrich received his undergraduate degree from Boston College, and an M.B.A. from the Amos Tuck School at Dartmouth College. We believe that Mr. Aldrich is qualified to serve on our board of directors due to his experience in the life sciences industry as an entrepreneur and venture capitalist and his service on the boards of directors of other life sciences companies.

Dr. John P. Howe, III, M.D., is an Director of the Company. Dr. Howe is a recognized expert in international medicine and is a humanitarian leader. From 2001 through 2015, he served as the President and Chief Executive Officer of Project HOPE, an international health education and humanitarian assistance foundation, which operates more than 70 programs in 45 countries on five continents. During Dr. Howe’s tenure, Project HOPE expanded its areas of distributing medicine, treating infectious diseases and non-communicable diseases, and promoting the health education and life improvement of women and children. Before Project HOPE, Dr. Howe held the Distinguished Chair in Health Policy at The University of Texas Health Science Center at San Antonio; he served as the Center’s chief executive from 1985 through 2000 and is currently the President Emeritus. He is a board member of BB&T Bank, the Chinese Center for Communicable Disease Control and Prevention, the John E. Fogarty International Center at the National Institutes of Health and the Texas Biomedical Research Institute, among others. Among Dr. Howe’s numerous honors and awards are the U.S. Army’s Commander’s Award for Public Service, the Surgeon General’s Exemplary Service Award, and the Magnolia Award from the City of Shanghai, China. Dr. Howe is a published author of numerous articles, chapters and abstracts in medical journals, including the New England Journal of Medicine and the Annals of Internal Medicine, among others. Dr. Howe holds a Bachelor of Arts from Amherst College and an M.D. from Boston University School of Medicine.

Dr. John E. Sexton, Ph.D., is an Director of the Company. John E. Sexton, Ph.D., President of New York University (NYU), to the OvaScience Board of Directors. Dr. Sexton is the fifteenth President of NYU, serving in the role since 2001. He is a Fellow of the American Academy of Arts and Sciences, a member of the Council on Foreign Relations, and a past member of the Executive Committee of the Association of American Universities. He previously served as the Chairman of the Board of the Federal Reserve Bank of New York and Chair of the Federal Reserve Systems Council of Chairs. He was awarded the TIAA-CREF Hesburgh Award for Leadership Excellence, the Foreign Policy Association Medal, the NASPA President’s Award for advancing the quality of student life at NYU, and was named one of the “Top Ten College Presidents” by TIME magazine. Earlier in his career at NYU, he was the Dean and Benjamin Butler Professor of Law at NYU School of Law. Prior to NYU, Dr. Sexton was Law Clerk to Chief Justice Warren Burger of the United States Supreme Court and to Judges David Bazelon and Harold Leventhal of the United States Court of Appeals. Additionally, Dr. Sexton served as Special Master Supervising Pretrial Proceedings in the Love Canal Litigation. He also served as Professor of Religion and Department Chair at Saint Francis College. Dr. Sexton is a published author of several books, chapters, articles and Supreme Court briefs. Dr. Sexton holds a B.A. in History from Fordham College, an M.A. in Comparative Religion and a Ph.D. in History of American Religion from Fordham University, and a J.D. from Harvard Law School.

Mr. Jeffrey D. Capello is Independent Director of OvaScience, Inc., Jeffrey D. Capello has served as a member of our board of directors since March 2012. Since July 2014, Mr. Capello has served as the Executive Vice President and Chief Financial Officer of Ortho-Clinical Diagnostics, which was acquired by the Carlyle Group from Johnson & Johnson, with responsibility for global finance and business development. Prior to his role at Ortho-Clinical Diagnostics, Mr. Capello served as Chief Financial Officer and Executive Vice President of Boston Scientific from March 2010 to December 2013. At Boston Scientific, Mr. Capello was responsible for the worldwide management of Boston Scientific's finance, information systems, business development and corporate strategy functions. Mr. Capello joined Boston Scientific in June 2008 and served as Senior Vice President and Chief Accounting Officer until March 2010. Prior to joining Boston Scientific, he was the Senior Vice President and Chief Financial Officer with responsibilities for global finance and business development at PerkinElmer, Inc. from 2006 to 2008. Previously, he served as PerkinElmer's Vice President of Finance, Corporate Controller, Treasurer and Chief Accounting Officer from 2001 to 2006. Prior to his tenure at PerkinElmer, Mr. Capello was a Partner at PricewaterhouseCoopers LLP, both in the United States and in the Netherlands. Mr. Capello is a board member of Flex Pharma, Inc., a biotechnology company developing treatments for symptoms associated with neuromuscular conditions. Previously, Mr. Capello was a member of the board of directors of Sirtris Pharmaceuticals, Inc., which was acquired by GlaxoSmithKline in 2008, and served as the Chair of its audit committee. Mr. Capello holds a B.S. degree in business administration from the University of Vermont and an M.B.A. degree from Harvard Business School. Mr. Capello is also a certified public accountant.

Ms. Mary M. Fisher is Independent Director of OvaScience Inc. Mary Fisher has served as a member of our board of directors since June 2013. Ms. Fisher also serves as Chief Executive Officer and Director at Colorescience, Inc., a former division of SkinMedica, Inc., where she served as Chief Executive Officer from April 2008 to December 2012, when she led the sale of the company to Allergan, Inc. Prior to joining SkinMedica, Ms. Fisher was the Chief Operating Officer of Acorda Therapeutics, Inc., a biotechnology company focused on developing products for the treatment of central nervous system disorders, with responsibility for corporate strategy and business development, financial planning, sales and marketing, and manufacturing. Previously, Ms. Fisher was Vice President, Strategic Healthcare and Commercial Operations for Cephalon, Inc., with responsibility for product planning and marketing, managed care sales, and manufacturing. Her earlier experience includes positions at Immunex Corp. and Boehringer Ingelheim. She is also a member of the board of directors of Zeltiq Aesthetics, Inc., a publicly-traded medical technology company, and Neuroscience Nursing Foundation. We believe that Ms. Fisher is qualified to serve on our board based on her more than 25 years of experience in the pharmaceutical and biotechnology industries, including her executive experience.

Mr. Marc D. Kozin is Independent Director of OvaScience Inc. Marc Kozin has served as a member of our board of directors since January 2014. Mr. Kozin has been a Senior Advisor to L.E.K. Consulting, a global strategy consulting firm, since July 2011. Prior to that, Mr. Kozin served as president of L.E.K.'s North American practice for 15 years. Mr. Kozin currently serves as a member of the board of directors of UFP Technologies, Inc., a designer and manufacturer of engineered packaging solutions and engineered component products, DYAX Corp., a biopharmaceutical company, Endocyte, Inc., a biotechnology company developing treatments for cancer and inflammatory diseases, Flex Pharma, Inc., a biotechnology company developing treatments for symptoms associated with neuromuscular conditions, and two privately-held companies. He also serves on the strategic advisory board for Healthcare Royalty Partners, a global healthcare investment firm. Mr. Kozin holds a B.A., with distinction, in economics from Duke University and an M.B.A., with distinction, from The Wharton School, University of Pennsylvania. Mr. Kozin is qualified to serve on our board of directors due to his nearly 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management both domestically and internationally.

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: